Founder, Bridle Path Investments

Ruvin Orbach is the Founder of Bridle Path Investments, a healthcare and life sciences investment and advisory firm focused on identifying, financing, developing, and strategically positioning innovative companies across biotechnology, oncology, diagnostics, biologics, regenerative medicine, medical devices, and digital health.

​

Ruvin has worked at the intersection of science, capital, and commercialization, helping emerging healthcare companies access investment, establish strategic partnerships, and build relationships capable of accelerating promising technologies toward the market. Through Bridle Path, he has developed an extensive network of venture capital firms, family offices, ultra-high-net-worth investors, impact investors, healthcare institutions, and strategic partners in the United States and internationally.

​

Ruvin has represented and worked with a broad range of healthcare companies and investment organizations, including Epic Sciences, Exact Imaging, and Primary Peptides, among many others. He represented venture capitalists Lumira Ventures and Epic Capital. His work has included capital formation, investor representation, strategic advisory, business development, commercialization strategy, and connecting emerging companies with sophisticated sources of healthcare and life sciences capital.

​

Bridle Path's reach extends well beyond the United States. Ruvin has cultivated relationships throughout North America, Europe, Australia, and the Middle East, working with family offices, institutional investors, sovereign wealth-related stakeholders, healthcare organizations, and strategic partners to facilitate cross-border investment, company development, and commercialization opportunities.

​

In addition to Bridle Path, Ruvin is the Founder and an investor in CellxLife, a biotechnology company advancing innovative cellular immunotherapies designed to help prevent cancer recurrence and improve long-term patient outcomes. He leads the company's strategic direction, financing initiatives, investor relations, strategic partnerships, and commercialization efforts, working alongside scientific leadership and clinical collaborators to advance next-generation cancer therapies addressing significant unmet medical needs.

​

Ruvin also leads and has invested in Wonder Lab/WonderBank Holdings, a biotechnology and regenerative medicine platform focused on the development and commercialization of next-generation cellular therapies. Through WonderBank, he is helping build companies and partnerships around advanced cell technologies with potential applications across oncology, regenerative medicine, and other major disease areas.

At the center of Ruvin's work is a consistent strategy: identify differentiated science and technology, connect it with sophisticated capital and strategic partners, and help build the commercial infrastructure necessary to transform innovation into scalable companies and meaningful patient impact.